Welcome to ASCO Connection Discussion

The ASCO Connection Discussion forum is a space for oncology professionals and others with an interest in cancer care to ask and answer questions about every aspect of the field, from professional development advice to clinical conundrums. Everyone is welcome to participate: to ask a question or leave a response, first log in with your ASCO username and password. Please read the Discussion and Commenting Guidelines before you post a question or response. Contact our staff by email for assistance with the Discussion forum.

LOGIN TO START A DISCUSSION
Filter by Molecular Oncology Tumor Board
Molecular Oncology Tumor Board
ASCO University
Jun 14, 2017 6:46 AM
Read more to answer the following questions: 1) What defines sarcomatoid carcinoma on pathology? 2) Are additional ancillary studies, including immunostainings, beneficial to evaluate site of origin (this tumor was CD10 focally positive)? 3)What are the front line therapy options for this rare...
Molecular Oncology Tumor Board
ASCO University
May 10, 2017 8:23 AM
Read more to answer the following questions: 1) Is the location and morphology of this tumor significant clinically? 2) Prior to NGS what additional testing could have been performed? 3) Is one test for hereditary colon cancer better than the other? 4) What is the role of genetic counseling for...
Molecular Oncology Tumor Board
ASCO University
Apr 12, 2017 9:01 AM
Read more to answer the following questions: 1) Would you recommend clinical genetics consultation for BRCA testing? Would an expanded panel be beneficial? 2) What would be the next step in this patient’s management? 3) Is there a value in performing biopsy of liver lesion before starting any...
Molecular Oncology Tumor Board
ASCO University
Mar 15, 2017 9:47 AM
Read more to answer the following questions:
1. Who should get routine molecular testing at the time of diagnosis of NSCLC and what genes should be included in the molecular panel?
2. What is the proper timing of testing and sequencing of available therapies?
3. What treatment options are available...
Molecular Oncology Tumor Board
ASCO University
Feb 15, 2017 8:30 AM
Read more to answer the following questions:
1.    Recognize the diagnosis of CML and importance of bone marrow biopsy at presentation.
2.    Apply considerations when choosing initial therapy.
3.    Recognize when to switch therapy when response is suboptimal.
4.    Identify how to treat...

Pages